| Literature DB >> 33660221 |
Tomer Illouz1,2, Arya Biragyn3, Milana Frenkel-Morgenstern4, Orly Weissberg4, Alessandro Gorohovski4, Eugene Merzon5, Ilan Green5, Florencia Iulita6,7,8,9, Lisi Flores-Aguilar10, Mara Dierssen11,12,13, Ilario De Toma14,15,16, Hefziba Lifshitz17, Stylianos E Antonarakis18,19,20, Eugene Yu21,22, Yann Herault23, Marie-Claude Potier24, Alexandra Botté24, Randall Roper25, Benjamin Sredni26, Ronit Sarid24, Jacqueline London27, William Mobley28, Andre Strydom29,30, Eitan Okun31,32,33.
Abstract
The current SARS-CoV-2 outbreak, which causes COVID-19, is particularly devastating for individuals with chronic medical conditions, in particular those with Down Syndrome (DS) who often exhibit a higher prevalence of respiratory tract infections, immune dysregulation and potential complications. The incidence of Alzheimer's disease (AD) is much higher in DS than in the general population, possibly increasing further the risk of COVID-19 infection and its complications. Here we provide a biological overview with regard to specific susceptibility of individuals with DS to SARS-CoV-2 infection as well as data from a recent survey on the prevalence of COVID-19 among them. We see an urgent need to protect people with DS, especially those with AD, from COVID-19 and future pandemics and focus on developing protective measures, which also include interventions by health systems worldwide for reducing the negative social effects of long-term isolation and increased periods of hospitalization.Entities:
Keywords: COVID-19; Down syndrome; Immune dysregulation; SARS-CoV-2; Vaccine
Mesh：
Substances：
Year: 2021 PMID： 33660221 PMCID： PMC7929736 DOI： 10.1007/s12017-021-08651-5
Source DB: PubMed Journal: Neuromolecular Med ISSN： 1535-1084 Impact factor: 3.843